SCHEMBL571003

SCHEMBL571003

NC(=O)c1cc(F)cc2c1C(=O)N(C1CCN(C3CCC(F)(F)CC3)CC1)C2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 12/20 1.00
PARP2 Q9UGN5 5/20 1.00
CYP2D6 P10635 1/20 1.00
CYP2B6 P20813 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29357315 1.00 PARP1 (1.00) PARP1PARP2CYP2D6CYP2B6
SCHEMBL15662387 0.92 PARP1 (0.85) PARP1PARP2CYP2D6CYP2B6
SCHEMBL15662088 0.91 PARP1 (0.83) PARP1PARP2CYP2D6CYP2B6
SCHEMBL1881724 0.91 PARP1 (1.00) PARP1PARP2CYP2D6CYP2B6
SCHEMBL1860629 0.90 PARP1 (1.00) PARP1PARP2CYP2D6CYP2B6
SCHEMBL15662751 0.88 PARP1 (0.79) PARP1PARP2CYP2D6CYP2B6
SCHEMBL1865934 0.88 PARP1 (0.79) PARP1PARP2CYP2D6CYP2B6
SCHEMBL1876306 0.87 PARP1 (0.77) PARP1PARP2CYP2D6CYP2B6
SCHEMBL30417915 0.87 PARP1 (0.77) PARP1PARP2CYP2D6CYP2B6
SCHEMBL1874517 0.87 PARP1 (0.77) PARP1PARP2CYP2D6CYP2B6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2454236-B1 3-OXO-2,3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2019-09-04 EP claimed
US-8877944-B2 3-oxo-2,3-dihydro-1H-isoindole-4-carboxamides as PARP inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-11-04 US claimed
EP-2600867-A1 THERAPEUTIC COMBINATION COMPRISING A PARP-1 INHIBITOR AND AN ANTI-NEOPLASTIC AGENT Nerviano Medical Sciences S.r.l. (IT) 2013-06-12 EP claimed
US-20130129841-A1 THERAPEUTIC COMBINATION COMPRISING A PARP-1 INHIBITOR AND AN ANTI-NEOPLASTIC AGENT NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-05-23 US claimed
CN-103052390-A Therapeutic combination comprising parp-1 inhibitor and anti-neoplastic agent NERVIANO MEDICAL SCIENCES SRL 2013-04-17 CN claimed
US-20120245142-A1 3-OXO-2,3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-09-27 US claimed
EP-2454236-A1 3-OXO-2, 3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2012-05-23 EP claimed
WO-2012016876-A1 THERAPEUTIC COMBINATION COMPRISING A PARP-1 INHIBITOR AND AN ANTI-NEOPLASTIC AGENT NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-02-09 WO claimed
WO-2011006794-A9 3-OXO-2, 3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-05 WO claimed
US-12605450-B2 C3-carbon linked glutarimide Degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2026-04-21 US disclosed
EP-4717317-A2 N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION C4 Therapeutics, Inc. (US) 2026-04-01 EP disclosed
US-12570626-B2 Degraders and degrons for targeted protein degradation C4 THERAPEUTICS, INC. (US) 2026-03-10 US disclosed
EP-3641762-B1 N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION C4 THERAPEUTICS INC (US) 2026-02-18 EP disclosed
EP-4694883-A2 COMBINATIONS COMPRISING AN ATR INHIBITOR AND A PARP INHIBITOR AND METHODS OF USE THEREOF Jazz Pharmaceuticals Therapeutics, Inc. (US) 2026-02-18 EP disclosed
US-20120245142-A1 3-OXO-2,3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-09-27 US disclosed
US-20120245142-A1 3-OXO-2,3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-09-27 US disclosed
EP-2454236-A1 3-OXO-2, 3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2012-05-23 EP disclosed
WO-2012016876-A1 THERAPEUTIC COMBINATION COMPRISING A PARP-1 INHIBITOR AND AN ANTI-NEOPLASTIC AGENT NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-02-09 WO disclosed
WO-2011006794-A9 3-OXO-2, 3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-05 WO disclosed
WO-2011006794-A9 3-OXO-2, 3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12605450-B2 C3-carbon linked glutarimide Degronimers for target protein degradation NEDD4, UBE3A, UBE3C PARP1 2146/4885PARP2 1679/4885CYP2D6 4126/4885
US-20130129841-A1 THERAPEUTIC COMBINATION COMPRISING A PARP-1 INHIBITOR AND AN ANTI-NEOPLASTIC AGENT PARP1, PARP2, TOP1 PARP1 1/4885PARP2 2/4885CYP2D6 1945/4885
US-12570626-B2 Degraders and degrons for targeted protein degradation ADRM1, UCHL3, USP30 PARP1 3731/4885PARP2 2943/4885CYP2D6 1112/4885
US-20120245142-A1 3-OXO-2,3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS PARP1, PARP2, PARP3 PARP1 1/4885PARP2 2/4885CYP2D6 2107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.